Literature DB >> 29321233

Effect of psychostimulants on blood pressure profile and endothelial function in narcolepsy.

Adriana Bosco1, Régis Lopez1, Lucie Barateau1, Sofiene Chenini1, Carole Pesenti1, Jean-Louis Pépin1, Isabelle Jaussent1, Yves Dauvilliers2.   

Abstract

OBJECTIVE: To assess the effect of psychostimulant treatments on the 24-hour blood pressure (BP) profile of patients with narcolepsy type 1 (NT1).
METHODS: Heart rate (HR) and BP were monitored for 24 hours and morning endothelial function was evaluated in 160 consecutive patients with NT1: 68 untreated (41 male, median age 34.9 years), 54 treated (32 male, median age 40.9 years), and 38 evaluated twice (21 male, median age 32 years), before and during treatment.
RESULTS: Patients treated for NT1 showed higher 24-hour, daytime, and nighttime diastolic BP and HR values compared with the untreated group. Similarly, HR as well as 24-hour and daytime systolic BP were increased during treatment in the group evaluated twice. The combination of stimulant and anticataplectic drugs showed a synergistic effect on BP, without differences among stimulant categories. Based on 24-hour BP monitoring, hypertension was diagnosed in 58% of treated patients and in 40.6% of untreated patients. After adjustments for age, sex, and body mass index, the percentage of REM sleep remained associated with 24-hour hypertension in untreated and treated patients. Endothelial function was comparable in treated and untreated patients.
CONCLUSIONS: The finding that patients with NT1 treated with psychostimulants have higher diastolic BP and HR than untreated patients suggests an increased long-term risk of cardiovascular diseases that requires careful follow-up and specific management.
© 2018 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29321233     DOI: 10.1212/WNL.0000000000004911

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

Review 1.  Neurological Sleep Disorders and Blood Pressure: Current Evidence.

Authors:  Meghna P Mansukhani; Naima Covassin; Virend K Somers
Journal:  Hypertension       Date:  2019-09-03       Impact factor: 10.190

2.  Metabolic-Syndrome-Related Comorbidities in Narcolepsy Spectrum Disorders: A Preliminary Cross-Sectional Study in Japan.

Authors:  Kunihiro Futenma; Yoshikazu Takaesu; Masaki Nakamura; Kenichi Hayashida; Noboru Takeuchi; Yuichi Inoue
Journal:  Int J Environ Res Public Health       Date:  2022-05-22       Impact factor: 4.614

3.  A randomized study of solriamfetol for excessive sleepiness in narcolepsy.

Authors:  Michael J Thorpy; Colin Shapiro; Geert Mayer; Bruce C Corser; Helene Emsellem; Giuseppe Plazzi; Dan Chen; Lawrence P Carter; Hao Wang; Yuan Lu; Jed Black; Yves Dauvilliers
Journal:  Ann Neurol       Date:  2019-03       Impact factor: 10.422

Review 4.  Recent advances in treatment for narcolepsy.

Authors:  Lucie Barateau; Yves Dauvilliers
Journal:  Ther Adv Neurol Disord       Date:  2019-09-26       Impact factor: 6.570

5.  Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial.

Authors:  Yves Dauvilliers; Johan Verbraecken; Markku Partinen; Jan Hedner; Tarja Saaresranta; Ognian Georgiev; Rumen Tiholov; Isabelle Lecomte; Renaud Tamisier; Patrick Lévy; Catherine Scart-Gres; Jeanne-Marie Lecomte; Jean-Charles Schwartz; Jean-Louis Pépin
Journal:  Am J Respir Crit Care Med       Date:  2020-05-01       Impact factor: 21.405

6.  Management Of Excessive Sleepiness In Patients With Narcolepsy And OSA: Current Challenges And Future Prospects.

Authors:  Ashima S Sahni; Melissa Carlucci; Malik Malik; Bharati Prasad
Journal:  Nat Sci Sleep       Date:  2019-10-23

Review 7.  Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution: A Lower-Sodium Alternative for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy.

Authors:  Yves Dauvilliers; Richard K Bogan; Karel Šonka; Markku Partinen; Nancy Foldvary-Schaefer; Michael J Thorpy
Journal:  Nat Sci Sleep       Date:  2022-03-29

8.  Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial.

Authors:  Thomas Roth; Yves Dauvilliers; Michael J Thorpy; Clete Kushida; Bruce C Corser; Richard Bogan; Russell Rosenberg; Jordan Dubow; David Seiden
Journal:  CNS Drugs       Date:  2022-04-05       Impact factor: 5.749

9.  What Works for One May Not Work for Another: A New Warning for Modafinil.

Authors:  Harim Kim; Girma M Ayele; Rediet T Atalay; Siham Hussien; Bereket Tewoldemedhin; Miriam B Michael; Steven M Scharf
Journal:  Cureus       Date:  2022-07-26

10.  Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients.

Authors:  Rebecca Evans; Haruhide Kimura; Robert Alexander; Ceri H Davies; Hélène Faessel; Deborah S Hartman; Takashi Ishikawa; Emiliangelo Ratti; Kohei Shimizu; Motohisa Suzuki; Shinichiro Tanaka; Hiroshi Yukitake; Yves Dauvilliers; Emmanuel Mignot
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-22       Impact factor: 12.779

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.